AKUS - AKUS STOCK NEWS

Akouos announced that its CEO, Manny Simons, will present at two upcoming virtual investor conferences on September 13, 2021. The first event is the H.C. Wainwright 23rd Annual Global Investment Conference, featuring a pre-recorded fireside chat available on demand starting at 7:00 a.m. EDT. The second event is the Morgan Stanley Virtual Global Healthcare Conference, with a live fireside chat at 5:00 p.m. EDT. Webcasts for both events will be accessible on Akouos’s website, with archived replays available for 90 days.

Akouos, Inc. (NASDAQ: AKUS) announced the European Commission's designation of AK-OTOF as an orphan drug for treating otoferlin gene-mediated hearing loss. The company is advancing both AK-OTOF and AK-antiVEGF towards planned IND submissions in 2022. Financially, Akouos reported a net loss of $22.7 million for Q2 2021, with R&D expenses increasing to $17.1 million. As of June 30, 2021, the company's cash position was $271.8 million, expected to fund operations for at least two years.

Akouos (NASDAQ: AKUS) announced that the European Medicines Agency's Committee for Orphan Medicinal Products has issued a positive opinion for AK-OTOF, a gene therapy for otoferlin gene-mediated hearing loss. This opinion was adopted by the European Commission. AK-OTOF previously received Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. FDA. This gene therapy targets a significant unmet medical need, as approximately 20,000 individuals in the U.S. and Europe are affected. Orphan drug designation provides benefits such as regulatory assistance and potential market exclusivity.

Akouos, a precision genetic medicine company, will have its CEO, Manny Simons, present at two virtual investor conferences in August 2021. The first is the BTIG Biotechnology Conference on August 10 at 2:30 p.m. EDT, followed by the Canaccord Genuity 41st Annual Growth Conference on August 12 at 12:00 p.m. EDT. Interested investors can access the live webcast via Akouos's website, with an archived replay available for 90 days. Akouos focuses on developing gene therapies for individuals with disabling hearing loss, leveraging a proprietary AAV vector library.

Akouos, Inc. (Nasdaq: AKUS) announced key developments including the appointment of Dr. Kathy Reape as chief development officer, enhancing its leadership team. The FDA granted both Orphan Drug and Rare Pediatric Disease designations for AK-OTOF, targeting otoferlin gene-mediated hearing loss, with plans for an IND submission in 2022. Financially, the company reported a net loss of $16.1 million for Q1 2021, an increase from $10.4 million in Q1 2020, alongside R&D expenses rising to $11.3 million. Akouos maintains a cash position of $286.6 million to fund operations for at least two years.

Akouos, a precision genetic medicine company, has announced promising results from nonclinical data on its gene therapies AK-OTOF and AK-antiVEGF during the ASGCT 24th Annual Meeting. The studies demonstrated full-length expression of otoferlin in non-human primates, with significant restoration of auditory function in Otof knockout mice. The company plans to submit Investigational New Drug applications for both therapies in 2022, aiming to address critical unmet needs in hearing loss and vestibular schwannoma treatment.

Akouos (NASDAQ: AKUS) announces that its CEO, Manny Simons, will participate in a fireside chat at the Bank of America 2021 Virtual Healthcare Conference on May 12, 2021, at 2:00 p.m. EDT. Akouos focuses on developing gene therapies aimed at restoring hearing for individuals with disabling hearing loss. The chat will be live-streamed on the Akouos website, and a replay will be available for 30 days post-event. Founded in 2016 and based in Boston, Akouos specializes in precision genetic medicine.

Akouos (NASDAQ: AKUS) has appointed Dr. Kathy Reape as Chief Development Officer, bringing over 20 years of pharmaceutical industry experience, particularly in gene therapy. Dr. Reape's expertise includes significant roles at Spark Therapeutics, where she contributed to the FDA approval of LUXTURNA, the first in vivo gene therapy for a retinal disorder. Her leadership is expected to enhance Akouos' AK-OTOF and AK-antiVEGF programs, targeting IND submissions in 2022. The company aims to develop gene therapies for disabling hearing loss, a condition with limited treatment options.

Akouos, Inc. (NASDAQ: AKUS) announced the presentation of new nonclinical data at the American Society of Gene and Cell Therapy 24th Annual Meeting from May 11-14, 2021. The data will support the clinical development of two gene therapies: AK-OTOF for otoferlin gene-mediated hearing loss and AK-antiVEGF for vestibular schwannoma treatment. Presentations will occur on May 11, highlighting in vitro and in vivo analyses, auditory function recovery in mouse models, and tolerability of delivery approaches in non-human primates.